Camurus AB (publ) (CAMRF)
- Previous Close
61.90 - Open
61.90 - Bid 56.30 x 27000
- Ask 63.90 x 28000
- Day's Range
61.90 - 61.90 - 52 Week Range
46.15 - 66.69 - Volume
100 - Avg. Volume
1 - Market Cap (intraday)
3.57B - Beta (5Y Monthly) 0.86
- PE Ratio (TTM)
81.05 - EPS (TTM)
0.74 - Earnings Date May 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
www.camurus.comRecent News: CAMRF
View More
Performance Overview: CAMRF
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CAMRF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CAMRF
View MoreValuation Measures
Market Cap
3.57B
Enterprise Value
3.28B
Trailing P/E
80.60
Forward P/E
38.31
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
18.49
Price/Book (mrq)
10.39
Enterprise Value/Revenue
17.02
Enterprise Value/EBITDA
55.94
Financial Highlights
Profitability and Income Statement
Profit Margin
22.94%
Return on Assets (ttm)
10.35%
Return on Equity (ttm)
17.91%
Revenue (ttm)
1.87B
Net Income Avi to Common (ttm)
428.39M
Diluted EPS (ttm)
0.74
Balance Sheet and Cash Flow
Total Cash (mrq)
2.85B
Total Debt/Equity (mrq)
0.52%
Levered Free Cash Flow (ttm)
121.47M